AR012010A1 - Metodo para el procesamiento de una solucion acuosa de proteina c activada - Google Patents

Metodo para el procesamiento de una solucion acuosa de proteina c activada

Info

Publication number
AR012010A1
AR012010A1 ARP980101908A ARP980101908A AR012010A1 AR 012010 A1 AR012010 A1 AR 012010A1 AR P980101908 A ARP980101908 A AR P980101908A AR P980101908 A ARP980101908 A AR P980101908A AR 012010 A1 AR012010 A1 AR 012010A1
Authority
AR
Argentina
Prior art keywords
activated protein
solution
processing
aqueous activated
aqueous
Prior art date
Application number
ARP980101908A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR012010A1 publication Critical patent/AR012010A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Abstract

Se hace referencia en general a un método para reducir la autodegradacion de la proteína C activada durante la elaboracion y la purificacion. Sese proporciona soluciones de proteína C activada acuosas y un método mejorado para la elaboracion conuna fuerza ionica superior a 150 mM y con un pH deaproximadamente 5,5 hasta uno inferior a 6,3.
ARP980101908A 1997-04-28 1998-04-24 Metodo para el procesamiento de una solucion acuosa de proteina c activada AR012010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
AR012010A1 true AR012010A1 (es) 2000-09-13

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980101908A AR012010A1 (es) 1997-04-28 1998-04-24 Metodo para el procesamiento de una solucion acuosa de proteina c activada
ARP980101909A AR015598A1 (es) 1997-04-28 1998-04-24 FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP980101909A AR015598A1 (es) 1997-04-28 1998-04-24 FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.

Country Status (35)

Country Link
US (4) US6162629A (es)
EP (2) EP0875563A3 (es)
JP (2) JP4383547B2 (es)
KR (2) KR100450856B1 (es)
CN (2) CN1227025C (es)
AR (2) AR012010A1 (es)
AT (1) ATE285788T1 (es)
AU (2) AU743531B2 (es)
BR (2) BR9809292A (es)
CA (2) CA2287267C (es)
CO (2) CO4950523A1 (es)
CZ (1) CZ298429B6 (es)
DE (1) DE69828330T2 (es)
DK (1) DK0875252T3 (es)
EA (2) EA004881B1 (es)
EG (1) EG23685A (es)
ES (1) ES2234072T3 (es)
HK (1) HK1016472A1 (es)
HU (2) HUP0003401A3 (es)
ID (2) ID22933A (es)
IL (2) IL132502A0 (es)
IN (2) IN187157B (es)
MY (2) MY118591A (es)
NO (2) NO995134L (es)
NZ (2) NZ337828A (es)
PE (2) PE84799A1 (es)
PL (2) PL195090B1 (es)
PT (1) PT875252E (es)
SI (1) SI0875252T1 (es)
SV (2) SV1998000051A (es)
TR (2) TR199902529T2 (es)
TW (2) TW585871B (es)
UA (2) UA73071C2 (es)
WO (2) WO1998048822A1 (es)
ZA (2) ZA983497B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
PE84799A1 (es) 1997-04-28 1999-09-16 Lilly Co Eli Metodos mejorados para el procesamiento de proteina c activada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
ATE320263T1 (de) * 1998-11-13 2006-04-15 Lilly Co Eli Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ES2195655T3 (es) * 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
ATE232739T1 (de) * 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
ATE264113T1 (de) * 1998-12-10 2004-04-15 Lilly Co Eli Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) * 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
AU2002327649A1 (en) 2001-09-19 2003-04-01 Mcmaster University Treatment of sepsis with tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
WO2003032904A2 (en) 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
KR101212025B1 (ko) 2002-06-21 2013-01-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
US20060198894A1 (en) * 2002-10-29 2006-09-07 Johanna Bentz Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
JP2007532486A (ja) * 2004-03-17 2007-11-15 カイロン コーポレイション 組織因子経路インヒビターの投与による重度の市中肺炎の処置
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
JP5094850B2 (ja) * 2006-05-31 2012-12-12 ジェンザイム コーポレーション 酵素活性の促進のための多糖の使用
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
RU2476442C2 (ru) * 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20190045414A (ko) * 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN102301235B (zh) * 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013151727A1 (en) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106573040B (zh) 2014-04-16 2021-07-06 Zz生物技术有限责任公司 治疗异常皮肤瘢痕形成
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
CN109640961B (zh) * 2016-06-01 2021-11-02 施维雅知识产权英国有限公司 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
PE84799A1 (es) 1997-04-28 1999-09-16 Lilly Co Eli Metodos mejorados para el procesamiento de proteina c activada
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
TW585871B (en) 2004-05-01
TR199902529T2 (xx) 2000-02-21
EA199900980A1 (ru) 2000-04-24
DE69828330D1 (de) 2005-02-03
AU7258998A (en) 1998-11-24
AR015598A1 (es) 2001-05-16
EA004881B1 (ru) 2004-08-26
EP0875252A2 (en) 1998-11-04
EP0875252B1 (en) 2004-12-29
TWI242443B (en) 2005-11-01
US6162629A (en) 2000-12-19
WO1998048818A1 (en) 1998-11-05
MY118591A (en) 2004-12-31
KR100564189B1 (ko) 2006-03-27
KR20010020242A (ko) 2001-03-15
HUP0003401A3 (en) 2003-01-28
IL132502A0 (en) 2001-03-19
CA2288143A1 (en) 1998-11-05
PL336889A1 (en) 2000-07-17
EP0875563A2 (en) 1998-11-04
ID23172A (id) 2000-03-23
BR9809292A (pt) 2000-07-04
EG23685A (en) 2007-05-09
MY120984A (en) 2005-12-30
CN1254284A (zh) 2000-05-24
ZA983497B (en) 1999-10-25
IL132325A0 (en) 2001-03-19
IN187157B (es) 2002-02-16
JP2001524111A (ja) 2001-11-27
ES2234072T3 (es) 2005-06-16
KR20010020325A (ko) 2001-03-15
NZ337828A (en) 2001-06-29
HUP0100284A2 (hu) 2001-06-28
IN183798B (es) 2000-04-15
CN1261280A (zh) 2000-07-26
CZ298429B6 (cs) 2007-10-03
DK0875252T3 (da) 2005-04-25
CO4940438A1 (es) 2000-07-24
CA2288143C (en) 2012-08-21
CO4950523A1 (es) 2000-09-01
JP4383546B2 (ja) 2009-12-16
AU740753B2 (en) 2001-11-15
US6436397B1 (en) 2002-08-20
US6395270B1 (en) 2002-05-28
AU7161898A (en) 1998-11-24
IL132325A (en) 2005-07-25
CN1227025C (zh) 2005-11-16
PL195090B1 (pl) 2007-08-31
NO995134L (no) 1999-12-21
HK1016472A1 (en) 1999-11-05
SV1998000050A (es) 1999-01-13
CA2287267C (en) 2006-08-15
AU743531B2 (en) 2002-01-31
PE86299A1 (es) 1999-09-17
PT875252E (pt) 2005-03-31
UA73071C2 (en) 2005-06-15
HUP0003401A2 (hu) 2001-02-28
NO995198L (no) 1999-10-25
EA199900979A1 (ru) 2000-06-26
NO995134D0 (no) 1999-10-21
TR199902631T2 (xx) 2000-01-21
NZ500346A (en) 2001-08-31
EA002149B1 (ru) 2001-12-24
HU224826B1 (en) 2006-02-28
BR9809304A (pt) 2000-10-17
PE84799A1 (es) 1999-09-16
KR100450856B1 (ko) 2004-10-02
EP0875252A3 (en) 2000-07-26
ZA983496B (en) 1999-10-25
WO1998048822A1 (en) 1998-11-05
CZ381099A3 (cs) 2000-03-15
DE69828330T2 (de) 2005-10-13
ATE285788T1 (de) 2005-01-15
CA2287267A1 (en) 1998-11-05
CN1235638C (zh) 2006-01-11
US6159468A (en) 2000-12-12
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
EP0875563A3 (en) 2000-08-02
SV1998000051A (es) 1998-12-11
SI0875252T1 (en) 2005-06-30
HUP0100284A3 (en) 2003-08-28
AU740753C (en) 2002-10-10
BR9809304B1 (pt) 2011-02-08
PL195642B1 (pl) 2007-10-31
NO995198D0 (no) 1999-10-25
ID22933A (id) 1999-12-16
PL336420A1 (en) 2000-06-19
JP2001527543A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
AR012010A1 (es) Metodo para el procesamiento de una solucion acuosa de proteina c activada
DE69806498T2 (de) Behandlung von kontaktlinsen mit wässrigen, alkalicarbonat-haltigen lösungen
MY163027A (en) FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-(α) ASSOCIATED DISORDERS
DE59910083D1 (de) Verwendung von Thiazolidin- oder Pyrrolidinderivaten von Aminosäuren als antihyperglykämische Mittel
CO4830493A1 (es) Anticuerpos contra cd40 humano
AU7609687A (en) Agents for the treatment of arthroses
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
GB2302329A (en) Yeast strains
DE3650135T2 (de) Proteingewinnung.
DE3784728D1 (de) Reinigung von rekombinantem interleukin-1.
EP1329461B8 (en) Method of eliminating human serum albumin polymers
HK1047960B (zh) 含有螺旋菌(helicobacter)過氧化氫酶的c-終端部分的多肽碎段
BR9005763A (pt) Utilizacao de aminoacidos protegidos contra o ph do rumen na alimentacao do carneiro
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
ES2098379T3 (es) Procedimiento para la reactivacion de una proteina desnaturalizada.
YU295A (sh) Postupci za sprečavanje degradacije proteina c
ATE139118T1 (de) Ribozymenhemmer
GR3021668T3 (en) IMPROVEMENTS IN OR RELATING TO GLASS pH ELECTRODES
GB9604518D0 (en) Novel compounds
EE9900205A (et) Ensüümimeetod tsefalosporaan-7ß-(4-karboksübutaanamiid)happe valmistamiseks Escherichia coli's saadud Trigonopsis variabilis modifitseeritud D-aminohappe oksüdaasi abil
WO2000053785A3 (en) Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
DE3586795T2 (de) Absorptionsverbesserer fuer proteine.
Stolyarov et al. Analog of Helman-Feynman theorem in multichannel theory of quantum defect; Analog teoremy Gel'mana-Fejnmana v mnogokanal'noj teorii kvantovogo defekta
HU9801199D0 (en) Ph 536b variety of inbred sterility conserving sunflower line (helianthus annuus l.)

Legal Events

Date Code Title Description
FG Grant, registration